EBITDA: Income before interest, taxes, depreciation and amortization.
Vera Therapeutics, Inc. (VERA) had EBITDA of $-84.41M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-80.29M |
|
-- |
|
-- |
|
$83.93M |
|
$-83.93M |
|
$3.64M |
|
$-80.29M |
|
$-80.29M |
|
$-80.29M |
|
$-80.29M |
|
$-80.29M |
|
$-80.29M |
|
$-83.93M |
|
|
EBITDA |
$-84.41M |
63.85M |
|
63.85M |
|
$-1.26 |
|
$-1.26 |
|
| Balance Sheet Financials | |
$511.31M |
|
$1.16M |
|
$6.19M |
|
$517.50M |
|
$41.88M |
|
$74.65M |
|
$76.74M |
|
$118.62M |
|
$398.88M |
|
$398.88M |
|
$398.88M |
|
63.89M |
|
| Cash Flow Statement Financials | |
$-171.11M |
|
$113.62M |
|
$22.61M |
|
$92.65M |
|
$57.77M |
|
$-34.87M |
|
$26.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.21 |
|
-- |
|
-- |
|
0.16 |
|
0.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-171.64M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.13% |
|
-20.13% |
|
-15.52% |
|
-16.96% |
|
$6.24 |
|
$-2.69 |
|
$-2.68 |
|